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osting by EAbstract Background: The poor outlook of cervical carcinoma, a human papillomavirus (HPV)-
related cancer mandates the search for new treatment modalities. Therapeutic targeting of tumor
vasculature is a promising strategy. The aim was to study angiogenesis in cervical carcinoma in
terms of VEGF expression and assessment of microvascular density (MVD) in relation to HPV
antigen expression.
Methods: Thirty parafﬁn blocks of cervical carcinoma were studied for the immune expression of
VEGF and MVD utilizing CD34 monoclonal antibody. Statistical analysis of these immunopheno-
types in relation to tumor type, grade and HPV antigen expression was performed.
Results: This retrospective study comprised of 17 squamous cell carcinomas, 11 adenocarcinomas
and two adenosquamous carcinomas. Eleven cases were low grade and 19 were high-grade cases.
VEGF expression was detected in 100% of cases. The relation between carcinoma grade and VEGF
expression and MVD was statistically signiﬁcant. There was no relation between VEGF intensity
and tumor type although more intense VEGF staining tended to occur in cervical adenocarcinomas.
VEGF density was signiﬁcantly lower in squamous cell carcinomas compared to adenocarcinomas.
Mean MVD was 50.37 ± 20.0. The relation between MVD and VEGF expression was statistically
signiﬁcant. HPV immune expression was detected in 93.33% of cases. The relation between HPVss: Department of Pathology,
oo.com (B.M. El Sabaa).
ersity Faculty of Medicine.
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48 B.M. El Sabaa et al.antigen expression and each of tumor histotype and grade was not statistically signiﬁcant. There
was a statistically signiﬁcant relation between HPV antigen expression and each of MVD and
VEGF intensity. Multivariate statistical analysis showed MVD as an independent predictor of car-
cinoma grade.
Conclusion: VEGF was expressed in 100% of studied cervical carcinoma. There was a statistically
signiﬁcant relation between VEGF expression and MVD. Since HPV antigen expression was signif-
icantly correlated with MVD and VEGF staining intensity, we provide evidence that HPV infection
may augment tumor angiogenesis in cervical carcinoma. MVD emerged as an independent predictor
of cervical carcinoma grade and hence of progressive behavior.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Cervical cancer is a worldwide public health problem being the
second most common cancer in females after breast cancer.1 In
Egypt, the latest census by the National Cancer Institute in
Cairo in 2003 showed predominance of cervical over endome-
trial carcinoma.2
The latest WHO classiﬁcation of cervical tumors 3 classiﬁes
epithelial malignancies mainly into four main groups: squa-
mous carcinomas; adenocarcinomas; neuro-endocrine tumors;
and others including adenosquamous carcinomas.4
Carcinoma of the cervix is considered a sexually transmissi-
ble disease.5 At the present time, viral agents particularly
human papillomavirus are believed to be the most likely
factors incriminated in the pathogenesis.6
Approximately 200 types of human papillomavirus (HPV)
have been identiﬁed, of which 85 have been genotypically char-
acterized.7 About 40 different types of HPV speciﬁcally infect
the genital area.8 According to their malignant potential, these
viruses can be classiﬁed as high- or low-risk types. The high-risk
types (predominantlyHPV-16 and -18) are related to high-grade
intraepithelial lesions and invasive cervical carcinoma.9
However, most HPV infections either regress spontane-
ously or progress to cancer after a long period of latency.10
Therefore, it was inferred that additional requirements other
than HPV infection are likely to be needed for neoplastic
transformation of cervical epithelial cells.10
There is accumulating evidence that angiogenesis plays a pivotal
role in cervical carcinogenesis.11 However, little is known about
the role of viral oncoproteins in regulating angiogenesis.12
Angiogenesis is the development of new blood vessels from
pre-existing vasculature.13 When a tumor launches the growth
of new vessels, it is said to have undergone an ‘‘angiogenic
switch’’. The principal trigger for this event appears to be hy-
poxia. Newly formed blood vessels will further promote tumor
cell proliferation 14 and increase the possibility of metastasis.15
A group of angiogenic stimulators and inhibitors regulate
the process of angiogenesis 16 Angiogenic stimulators include
vascular endothelial growth factor (VEGF), platelet derived
growth factor (PDGF), acidic and basic ﬁbroblast growth fac-
tors (FGF), transforming growth factors-a and b (TGF a and
b) and others.17 On the other hand, angiogenic inhibitors as
angiostatin and endostatin exist to prevent excessive neoangio-
genesis. Under normal circumstances, there is an equilibrium
between pro and anti-angiogenic factors, this balance is dis-
rupted in malignancy thereby favoring promotion of tumor
angiogenesis.18A great deal of attention has been focused on therapy that
can interrupt angiogenesis. Anti-angiogenic therapy may tar-
get endothelial cells directly, suppress the production and or
action of pro-angiogenic peptides or augment the release of
antiangiogenic factors within the tumor.19
Microvascular density (MVD) is a commonly used marker
for estimation of angiogenesis.20 Measuring MVD necessitates
labeling the vessels to be counted using antibodies against any
of the antigens naturally expressed by endothelial cells like F-
VIII, CD31, CD34 and CD105.20 Different methods have been
used for counting MVD, including manual counting of vascu-
lar hotspots and computerized image analysis.21
VEGF represents the major inducer of angiogenesis.16,22 It
is encoded by the human VEGF-A gene, on chromosome
6p21.3 22 and belongs to the VEGF superfamily of growth
factors which also includes VEGF-B, C, D, E and placental
growth factor (PlGF).23 VEGF exerts its biologic effect through
interaction with transmembrane tyrosine kinase receptors
(VEGFR). In tumors, VEGF expression is induced in response
to hypoxia, genetic and cytokine stimulation.24
Several functions have been described for VEGF including
acting as a potent mitogen for vascular endothelial cells,25
increasing microvascular permeability,26 degradation of extra-
cellular matrix,23 acting as an antiapoptotic factor for endothe-
lial cells24,26 in addition to mobilizing bone marrow-derived
endothelial cell precursors.23
In the present work we aimed at studying the role of angio-
genesis as measured by microvascular density and expression
of vascular endothelial growth factor (VEGF) in relation to
the status of HPV infection in some cases of cervical carcinoma.
2. Methods
This retrospective study was approved by the Ethics Committee
of Alexandria Faculty of Medicine. It consisted of 30 consecu-
tive cases of clinically and histologically proven cervical carci-
nomas. Patients were diagnosed and treated at the Alexandria
University Hospital, Alexandria, Egypt, between May 2007
and April 2009. All tissue samples were formalin ﬁxed and par-
afﬁn-embedded. Data about tumor stage were not always avail-
able so this parameter was not considered in analysis.
2.1. Histopathological examination
Five micron-thick sections cut from archival parafﬁn blocks
were H&E stained and examined microscopically to determine
tumor histologic type and grade. Squamous cell carcinomas
were graded according to the modiﬁed Broders’ grading system
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addition to the degree of differentiation.27 Adenocarcinomas
were graded according to the recommendations of the Associ-
ation of Directors of Anatomic and Surgical Pathology28
(grades I–III) taking into consideration architectural as well
as nuclear criteria. For statistical purposes, cases of grades I
and II were grouped together as low-grade tumors (11 cases,
36.7%), while grades III and IV cases were grouped together
as high-grade tumors (19 cases, 63.3%).
2.2. Immunohistochemistry
Heat-induced epitope retrieval was performed by microwaving
the sections in EDTA (1 mM, pH 8.0) for VEGF and in citrate
buffer (10 mM, pH 6.0) (Thermo Fisher, Fremont, USA) for
CD34 and HPV at 700W, 4 times, 2 min each. Endogenous
peroxidase activity and nonspeciﬁc binding were blocked.
Three primary, mouse monoclonal antibodies were
employed; VEGF antibody (Ab-7 Cat. #MS-1467-R7), human
papillomavirus antibody (Ab-3, Clone K1H8, Cat. #MS-1826-
R7) and CD34 antibody (Ab-1, Clone QBEnd/10, Cat. #MS-
363-R7). All three primary antibodies were supplied in a pre-
diluted format and were incubated with tissue sections at
4 C overnight. (Thermo Fisher Scientiﬁc Inc., Fremont, CA,
USA). The reaction product was visualized using the streptavi-
din–biotin peroxidase system with Diaminobenzidine as a
chromogen (UltraVision Detection System Anti-Mouse,
HRP/DAB, Cat #TM-015-HD, Thermo Fisher, Fremont,
CA, USA) according to the manufacturer’s protocol.
Sections without primary antibodies served as negative controls.
Blood vessels in normal cervical tissue adjacent to the tumor served
as internal positive controls for VEGF and CD34 immunostaining
whereas commercially available positive control slides were used as
positive control for HPV immunostaining (Cat. #MS-1826-CS7,
l=0?>Thermo Fisher, Fremont, CA, USA).29,30
Finally, sections were counterstained with hematoxylin,
dehydrated and mounted.
2.3. Assessment of immunostaining
2.3.1. VEGF immunostaining
Positive VEGF immunostaining was deﬁned as a cytoplasmic
and or membranous staining of tumor cells.31 VEGF-stained
sections were studied at 100· magniﬁcation to assess VEGF
staining density and intensity. VEGF density was deﬁned as
percentage of VEGF-stained tumor cells scored according to
a 2-teired scoring system31,32 whereby score 1 designated posi-
tive cytoplasmic staining in 650% and score 2 in >50% of
tumor cells. VEGF staining intensity was scored according
to a 4-teired system32 into score 0: negative, 1: weak, 2: mod-
erate and 3: strong staining. All sections were stained in a
single run to avoid procedural variations affecting the credence
of comparing VEGF intensity readings.
2.3.2. HPV-immunostaining
This was evaluated as either positive or negative, whereby any
number of tumorous or non-tumorous cells showing brown
nuclear staining qualiﬁed as a positive result.
2.3.3. CD34 immunostaining
A case was considered positive if any number of tumor vessel
endothelial cells showed cytoplasmic brown staining.2.4. Assessment of MVD
MVD was calculated according to the method described by
Weidner et al.21 CD34-stained sections were examined under
low magniﬁcation (100·) to determine the area of highest vas-
cularity (hot spot). Ten consecutive high power ﬁelds (HPFs)
(400·) were assessed within a hot spot and vessel count was
estimated in each HPF using the framework of an optical grid
mounted onto the eye piece. Ten MVD readings were obtained
for each tumor, the mean of which was recorded and expressed
as the number of vessels HPF.20,21
Microvessels were identiﬁed as any CD34 positive endothe-
lial cell or cluster of cells with or without visible lumen. In
dense vascular networks, each distinct branch was interpreted
as a single vessel. Large anastomosing sinusoidal vessels were
counted as a single vessel.33
3. Statistical analysis
Statistical analysis was performed using SPSS (Statistical
Package for Social Sciences, version 13.0, Chicago, USA).
3.1. Bivariate analysis
Continuous variables were expressed as mean ± standard
deviation (SD), while categorical variables were expressed as
numbers and percentages. Statistical relations between two
categorical variables were tested using Chi-square (v2) or
Fisher exact tests. Relations between categorical and continu-
ous variables were tested using t test and ANOVA. The level of
signiﬁcance was set at P 6 0.05.
3.2. Multivariate analysis
In order to identify possible predictors of biological behavior
of cervical carcinoma, all statistically signiﬁcant variables with
cervical carcinoma types or grade in the bivariate analysis were
introduced into a logistic regression model. Odds ratio and
95% conﬁdence intervals (CI) were calculated.
ROC curves were used to evaluate the speciﬁcity, sensitivity
and overall accuracy of the predictive variables. The value that
showed the highest overall accuracy was used as the cut-off
points of the continuous variables.
4. Results
In the current study, 30 cases of cervical carcinoma were in-
cluded. The mean age was 49.79 + 4.67 years ranging between
40 and 60 years. Histologically, 17 cases were squamous cell
carcinomas (56.7%), 11 adenocarcinomas (36.7%) while two
cases (6.7%) were adenosquamous carcinomas.
Cases of squamous cell carcinoma were classiﬁed into a case
(5.8%) of grade I, three cases (17.6%) of grade II, eight cases
(47.1%) of grade III and ﬁve cases (29.4%) of grade IV.Adenocar-
cinomas were classiﬁed into grade 1 in ﬁve cases (45.4%), grade II
in two cases (18.1%) and grade III in four cases (36.8%).
Both cases of adenosquamous carcinoma were high grade
(poorly differentiated glandular component).
Overall, 11 cases (36.7%) of low-grade carcinoma and 19
cases (63.3%) of high-grade carcinoma were included in the
present study.
Figure 1 VEGF immunostaining. (A) Grade II adenocarcinoma showing strong cytoplasmic VEGF immunostaining in both neoplastic
epithelial (thin arrow) and stromal cells (thick arrow). (B) Grade II adenocarcinoma showing moderate cytoplasmic VEGF
immunostaining ((A and B) anti-VEGF, 200·). (C) Grade III squamous cell carcinoma showing moderate cytoplasmic VEGF
immunostaining in epithelial cells. (D) Grade III squamous cell carcinoma showing heterogeneous cytoplasmic VEGF immunostaining
with weak staining in areas (arrow head) and strong intensity in others ((C and D) anti-VEGF, 400·).
Table 1 Relation between VEGF intensity and histologic
subtypes of cervical carcinoma.
VEGF intensity scores Total P
1 2 3
Histologic subtypes
Squamous cell carcinoma
No. 3 5 9 17 0.315
% 42.9 83.3 52.9 56.7
Adenocarcinoma
No. 4 1 6 11
% 57.1 16.7 35.3 36.7
Adenosquamous carcinoma
No. 0 0 2 2
% 0 0 11.8 6.7
P: statistically signiﬁcant at <0.05.
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4.1.1. VEGF immunostaining
Heterogeneous VEGF positive cytoplasmic and membranous
staining was seen both in neoplastic epithelial cells and in stro-
mal cells (Fig. 1A). In addition, endothelial lining of intratu-
moral blood vessels showed positive cytoplasmic staining
(internal control).
The difference in VEGF staining intensity among the three his-
tologic types of cervical carcinoma was statistically insigniﬁcant
(P= 0.315), while the difference in VEGF staining density was
statistically signiﬁcant (P= 0.002, Fisher exact test) with the high-
est VEGF density scores recorded in adenocarcinomas and lowest
values recorded in squamous cell carcinomas (Tables 1 and 2).
The relation between cervical carcinoma grade and VEGF
expression was statistically signiﬁcant (P 6 0.0001) (being
direct with VEGF staining intensity and inverse with VEGF
density) (Fig. 1A–D) (Tables 3 and 4).
4.1.2. CD34 immunostaining and assessment of MVD
CD34 positive cytoplasmic staining was seen in endothelial
cells lining intratumoral blood vessels and vessels in adjacent
normal cervical tissue (internal positive control). MVD values
ranged between 17.9 and 90.2 vessel/HPF with a mean of
50.37 ± 20.02.
The highest MVD values were recorded in adenosquamous
carcinomas (65.70 ± 10.60) (Fig. 2C), while the least valueswere recorded in squamous cell carcinomas (47.32 ± 18.42)
(Fig. 2A). However, the difference in MVD between the three
histologic types was statistically insigniﬁcant (P= 0.450).
The difference in mean MVD values between low-grade
(30.74 ± 8.25) and high-grade (61.74 ± 15.38) carcinomas
was statistically signiﬁcant (t test: 7.18, P 6 0.0001).
4.1.3. HPV immunostaining
HPV positive nuclear staining was seen in infected neoplastic
and non-neoplastic cells in 28 cases (93.3%).
Table 4 Relation between VEGF staining density and cervical
carcinoma grade.
Cervical carcinoma grades Total
Low grade High grade
VEGF density scores
1
No. 1 16 17
% 9.1 84.2 56.7
2
No. 10 3 13
% 90.9 15.8 43.3
Total
No. 11 19 30
% 100.0 100.0 100.0
P of Fisher exact test <0.0001*
* P: statistically signiﬁcant at <0.05.
Table 2 Relation between VEGF staining density and histo-
logic subtypes of cervical carcinoma.
VEGF density scores Total P
1 2
Histologic subtypes
Squamous cell carcinoma
No. 14 3 17
% 82.4 23.1 56.7
Adenocarcinoma
No. 2 9 11 0.002*
% 11.8 69.2 36.7
Adenosquamous carcinoma
No. 1 1 2
% 5.9 7.7 6.7
* P: statistically signiﬁcant at <0.05.
Table 3 Relation between VEGF staining intensity and
cervical carcinoma grade.
Cervical carcinoma grades Total
Low grade High grade
VEGF intensity scores
1
No. 7 0 7
% 63.6 0 23.3
2
No. 2 4 6
% 18.2 21.1 20.0
3
No. 2 15 17
% 18.2 78.9 56.7
Total
No. 11 19 30
% 100.0 100.0 100.0
v2 16.66
P value <0.0001*
* P: statistically signiﬁcant at <0.05.
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(Fig. 2E), all adenocarcinomas (11 cases) (Fig. 2F) and both
adenosquamous carcinomas (two cases) were positive. How-
ever, no statistical signiﬁcance was found between HPV
expression and histologic type (P= 0.304) or tumor grade
(P= 0.13). (Table 5).
4.2. Relationship between VEGF expression and MVD
The relation between VEGF staining intensity and MVD of
cervical carcinoma was statistically signiﬁcant (P= 0.0001)
(Table 6) and so was the inverse relation between VEGF stain-
ing density and MVD (P= 0.028). (Table 7).
4.3. Relationship between HPV expression and each of MVD
and VEGF expression
The relation between HPV expression and MVD was statisti-
cally signiﬁcant (t= 7.541, P 6 0.0001). Furthermore, therelation between VEGF staining intensity and HPV expression
was statistically signiﬁcant (P= 0.042); however, the relation
between VEGF staining density and HPV expression was not
(P= 0.179). (Tables 8 and 9).
4.4. Results of multivariate statistical analysis
In a logistic regression analysis, including cervical carcinoma
grade, MVD, VEGF intensity and density of expression;
MVD emerged as an independent predictor of cervical carci-
noma grade hence implying a poorer outcome. (P= 0.042)
(Table 10).
The sensitivity, speciﬁcity and overall accuracy of MVD
were 92.9%, 75% and 85.5%, respectively and the value of
MVD that recorded the highest overall accuracy (MVD=
40.01 vessel/HPF) was chosen as the cut-off point. According
to this value, cervical carcinomas with MVD values 640.01
vessel/HPF were of expected lower grade and carcinomas with
MVD>40.01 vessel/HPF were of expected higher grade. ROC
curve (Fig. 3) showed that the area under the curve is 0.790
(conﬁdence interval = 0.623–0.957, P= 0.007). Hence, MVD
could be used as a predictive test for cervical carcinoma grade.
5. Discussion
Cancer of cervix is the second most common cancer among
females worldwide with a ratio of mortality to incidence of
52%.34 The annual number of new cervical cancer cases in
Egypt in 2008 was 514 projected to increase by 93% to 846
in 2025.35
The poor outlook of cervical carcinoma necessitates the
search for new prognostic factors and therapeutic strategies.
One such promising strategy is targeting tumor blood vessels.
However, till the present time, the prognostic import of biolog-
ical determinants of angiogenesis and their putative role in
treatment of cervical carcinoma are not settled.36
The poor prognostic implication of MVD in cervical cancer
is well established,37 however; so far, reports concerning the
relation between VEGF and MVD in cervical cancer are pro-
foundly contradictory.38,39
VEGF expression in cervical carcinoma has been studied at
many levels including serum VEGF level,40 VEGF mRNA36
Figure 2 Assessment of MVD using CD34 antibody and HPV antigen immune expression. (A) Grade IV squamous cell carcinoma, (B)
grade II adenocarcinoma, (C) adenosquamous carcinoma, (A–C) showing CD34 positive-tumor blood vessels, (D) grade I
adenocarcinoma showing positive CD34 staining of individual endothelial cells forming no visible lumen (arrow). ((A–D) anti-CD34,
200·). (E) Grade II squamous cell carcinoma showing strong positive nuclear HPV immunostaining (arrow). (F) Grade II
adenocarcinoma showing strong positive nuclear HPV immunostaining (arrow). ((E and F) anti-HPV, 400·).
Table 5 Relation between HPV expression and cervical
carcinoma grade.
Cervical carcinoma grade Total
Low grade High grade
HPV expression
Positive
No. 9 19 28
% 81.8 100 93.3
Negative
No. 2 0 2
% 18.2 0 6.7
Total
No. 11 19 30
% 100.0 100.0 100.0
P of Fisher
exact test
0.13
P: statistically signiﬁcant at <0.05.
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chemically was the method adopted in the present study beingthe most practically applicable.41 Moreover, expression of
VEGF mRNA was not always found to parallel VEGF protein
expression, possibly due to epigenetic modiﬁcation.36
In the present study, VEGF expression was invariably
detected in all cases which points to the crucial role played
by VEGF in cervical carcinogenesis.41 Cytoplasmic VEGF
staining in tumor cells and adjacent stromal cells was previ-
ously reported.42 Immunoreactive stromal cells are most
probably considered to be macrophages that were attracted
to the tumor to phagocytose VEGF positive-tumor cell
debris.42
In the present work, expression of VEGF by endothelial
cells lining intratumoral microvessels was in keeping with pre-
vious observations43,44 In these articles, such endothelial cells
expressed mRNA of VEGF receptors implying that VEGF
molecules released by tumor cells became bound to their recep-
tors onto tumor vessel-endothelium. This receptor–ligand
interaction may provide a mechanism of retaining and concen-
trating VEGF, thereby maximizing its activity within the
tumor locale while preventing its diffusion elsewhere. This
ﬁnding stands in contrast to the ubiquitous distribution of
other pro-angiogenic peptides and thereby strongly favors
Table 6 Relation between VEGF intensity and MVD.
VEGF intensity N Mean S.D. Min. Max. ANO-VA P value
Score 1 7 28.1200 8.03770 17.90 39.40 12.301 0.0001*
Score 2 6 45.9167 15.26832 26.40 70.20
Score 3 17 61.1082 16.82993 34.50 90.20
Total 30 50.3727 20.02574 17.90 90.20
* P: statistically signiﬁcant at <0.05.
Table 7 Relation between VEGF density and MVD.
VEGF density Mean S.D. Min. Max. t P
650% 57.2782 16.97857 26.40 90.20 5.368 0.028*
>50% 41.3423 20.70976 17.90 77.20
Total 50.3727 20.02574 17.90 90.20
* P: statistically signiﬁcant at <0.05.
Table 8 Relation between HPV expression and VEGF
intensity.
VEGF intensity score Total
1 2 3
HPV
Positive
No. 5 6 17 28
% 71.4 100.0 100.0 93.3
Negative
No. 2 0 0 2
% 28.6 0 0 6.7
Total
No. 7 6 17 30
% 100.0 100.0 100.0 100.0
P 0.042*
* P: statistically signiﬁcant at <0.05.
Table 9 Relation between HPV expression and VEGF
density.
VEGF density score Total
1 2
HPV
Positive
No. 17 11 28
% 100.0 84.6 93.3
Negative
No. 0 2 2
% 0 15.4 6.7
Total
No. 17 13 30
% 100.0 100.0 100.0
P of Fisher
exact test
0.179
P: statistically signiﬁcant at <0.05.
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agents with minimal side effects.44
Most of the studied cases showed heterogeneous VEGF
staining intensity within the same tumor. The same ﬁnding
was previously reported by Tokumo et al.45 who attributed
such heterogeneity to regional ischemia stemming from regio-
nal differences in tumor cell growth. In addition, such staining
heterogeneity may be ascribed to varying binding afﬁnity and
degradation of VEGF isoforms released within the same tu-
mor.46 In the current study, like in others,47,48 a statistically
signiﬁcant positive correlation was found between VEGF
intensity and cervical carcinoma grade. Increasing tumor grade
is coupled with augmented proliferation rate which calls for in-
creased outgrowth of vascular supply. Such stresses generate a
state of chronic hypoxia within the tumor. Hypoxia, known to
be the most potent angiogenic stimulator, switches on tumor
angiogenesis via up regulating a set of genes including the
VEGF gene.49
On the other hand, the statistically signiﬁcant relation be-
tween VEGF density and cervical carcinoma grade was in-
verse. Other authors previously reporting the same ﬁnding45
posed that once a certain microvascular density is obtained,
growth reaches a plateau and the demand for VEGF declines,
causing a decrease in its expression (negative feedback).50 This
explanation can be further extrapolated to decipher the inverse
statistically signiﬁcant relation between VEGF density and
MVD (P= 0.028) which we reported as well as others.51
MVD is assumed to reﬂect past angiogenic activity whereby
the vascular network will remain long after the expression of
VEGF has ceased.52 This might explain why VEGF expression
– unlike MVD – had no prognostic value in the work of
Tjalma et al. 50
We were able to prove that VEGF density was higher in
adenocarcinomas compared to squamous cell carcinomas
and the relation was statistically signiﬁcant. Such a ﬁnding is
in line with results reported by Tjalma et al.50 This can be
ascribed to the fact that in the present study, most cases of
squamous cell carcinoma were of high grade (and hence of
low VEGF density) while most cases of adenocarcinoma were
of low grade (and hence of higher VEGF density).
Table 10 Logistic regression analysis.
Wald v2 P value Odds ratio 95.0% C.I.
Lower Upper
MVD 3.560 0.053* 1.570 0.983 2.508
HPV 0.01 0.98 231.34 0.03 456.11
VEGF intensity 0.60 0.44 2.58 0.24 28.03
VEGF density 0 0.99 1.74 0.99 3.123
* P: statistically signiﬁcant at <0.05.
Figure 3 ROC curve for accuracy of MVD to predict grade of
cervical carcinoma.
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nocarcinoma compared to other histotypes; however, no statis-
tical signiﬁcance was reached although previously reported.45
This could possibly be ascribed to the small number of adeno-
carcinomas enrolled in the present study.
MVD is considered a measure of tumor angiogenesis and a
signiﬁcant prognostic factor that correlates with increased like-
lihood of metastasis and worse prognosis in many tumor
types.36
In our work, MVD showed signiﬁcant correlation with
tumor grade. This ﬁnding comes in accord with previous
reports48 but still contradicts with others.53 Such discrepancy
may be attributed to variation in the studied histologic types
of cervical carcinoma, different methodologies adopted in
measuring MVD and the immunohistochemical markers used
for highlighting endothelial cells.
The highest values of MVD that we recorded were in
adenocarcinomas and the lowest values were in squamous cell
carcinomas. Both ﬁndings were previously reported.4,37 We
again ascribe our inability to reach statistical signiﬁcance to
the small number of adenocarcinomas included in the present
study.
Highlighting blood vessels immunohistochemically is an
essential prerequisite for measuring MVD. Several antibodies
have been employed for that purpose including factor VIII,CD105, CD34 and CD31 antibodies.54 Our selection of
CD34 was based on its superior sensitivity55 with detection
of a greater number of microvessels in cervical tumors com-
pared to other antibodies.56 Furthermore, it stains neoplastic
endothelium a deeper shade than normal endothelium.55 How-
ever, compared to other antibodies as CD31 and factor VIII, it
was found to be less speciﬁc in evaluating angiogenesis as it
stains non-endothelial cells (e.g. hematopoietic progenitor
cells) as well.57 For these considerations, it is imperative for
the evaluator to interpret the results of immunostaining in
the proper morphological context to better assess MVD as
an index of angiogenesis.
Since infection by high-risk types of HPV is strongly asso-
ciated with cervical carcinoma,7,8 we investigated the possible
association between virus infection and tumor angiogenesis.
HPV expression in cervical carcinoma has been studied at
many levels including estimation of serum HPV virus load,58
HPV DNA by PCR, in situ hybridization59 and immunohisto-
chemical detection of HPV antigens.60
In the current work we were able to immunohistochemi-
cally detect HPV expression in 93.3% of the studied cervical
carcinomas which is comparable to other data reported from
Muslim and Middle East countries as Morocco, (70.5%)61
and Iran (85.5%).62 In a study covering 22 countries and coor-
dinated by the International Agency for Research on Cancer
(IARC), the overall detection rates of HPV DNA were found
to vary little among different regions of the world (83–89%).63
Furthermore, in an Egyptian study,64 prevalence of HPV infec-
tion (detected by PCR) among Egyptian females 35 years and
above was 2.6% while HPV infection was positive in 94.3% of
cervical neoplastic lesions (pre-invasive and invasive). Actu-
ally, some authors allege that HPV causes practically 100%65
of cervical carcinomas, and ascribe the underestimation of its
prevalence in these tumors to ‘‘limitations of study
methodologies’’.66
All cases of cervical adenocarcinoma examined were posi-
tive for HPV which further endorses the notion that positivity
for HPV can be used to conﬁrm the endocervical origin of an
adenocarcinoma67.
In the current work, HPV immune expression of the studied
cases of cervical carcinoma showed positive statistically signif-
icant correlation with VEGF intensity. This is a novel ﬁnding
on the immunohistochemical level. The same import, however,
was reached by Song et al. who reported that VEGF expres-
sion is related to HPV load detected by PCR.68 The concept
of higher VEGF expression in HPV-16 E6 positive cells com-
pared to HPV-16 E6-negative ones was previously reported.69
The latter study group explained that HPV-16 E6 oncoprotein
might contribute to tumor angiogenesis by direct stimulation
VEGF expression and microvascular density in relation to high-risk-HPV infection in cervical carcinoma 55of the VEGF gene promoter.69 In the same context, other
researchers added that HPV-16 E6 oncoprotein interfered with
the ubiquitin mediated degradation of HIF-1a, a transcription
factor involved in activating VEGF gene promoter in response
to hypoxia.49 Furthermore, it has been pointed out that the
HPV-16 E7 oncoprotein enhanced the release of VEGF70
while, HPV-16 E5 oncoprotein up-regulated VEGF expression
through the activation of a diversity of signaling pathways.71
Not only did HPV immune expression correlate signiﬁ-
cantly with VEGF intensity but also with MVD of studied
tumors, a notion which lends credibility to the new concept
claiming that HPV infection stimulates tumor angiogenesis in
cervical carcinoma.
6. Conclusions
VEGF was expressed in all studied cases of cervical carcinoma.
There was a statistically signiﬁcant relation between VEGF
expression and MVD. Since HPV immune expression was sig-
niﬁcantly correlated with MVD and VEGF staining intensity,
we hereby provide further evidence that HPV infection may
augment tumor angiogenesis in cervical carcinoma. In cervical
carcinoma, MVD could be used as an independent predictor of
cervical carcinoma grade hence implying a poorer outcome
especially if anti-VEGF therapy is to be considered.
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